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Abstract Pediatric patients with end-stage renal failure due to
severe drug-resistant nephrotic syndrome are at risk of rapid
recurrence after renal transplantation. Treatment options in-
clude plasmapheresis, high-dose of cyclosporine
A/methylprednisolone and more recently—rituximab (anti-B
CD20 monoclonal depleting antibody). We report five patients
with immediate (1–2 days) post-transplant recurrence of ne-
phrotic syndrome, treated with this kind of combined therapy
including 2–4 weekly doses of 375 mg/m2 of rituximab. Only
two (of five) patients have showed full long-term remission,
while the partial remission was seen in two cases, and no
clinical effect at all was achieved in one patient. The correla-
tion between B CD19 cells depletion and clinical effect was
present in two cases only. Severe adverse events were present
in two patients, including one fatal rituximab-related acute
lung injury.
Conclusion: The anti-CD20 monoclonal antibody may be
not effective in all pediatric cases of rapid post-transplant re-
currence of nephrotic syndrome, and benefit/risk ratio must be
carefully balanced on individual basis before taking the deci-
sion to use this protocol.
What is Known:
• nephrotic syndrome may recur immediately after renal transplantation
• plasmapheresis combined with pharmacotherapy is used as rescue
management
• rituximab was reported as effective drug both in primary and post-
transplant nephrotic syndrome
What is New:
• rituximab may not be effective is several cases of post-transplant ne-
phrotic syndrome due to variety of underlying mechanisms of the dis-
ease, which may be or not be responsive to this drug
• there may be no correlation between drug-induced depletion of specific
B cells and clinical effect; this might suggest B-cell independent man-
ner of rituximab action
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Introduction
The recurrence of primary renal disease after renal transplan-
tation is a risk factor of inferior outcome [23]. Drug-resistant
nephrotic syndrome leading to end-stage renal failure is one
the most aggresive glomerular diseases recurring after renal
transplanation [1]. Immediate recurrence suggests the role of
preformed and circulating protein permeability factor(s),
which bind to specific targets in transplanted kidney.
Identification of responsible factor(s) is an ongoing subject
of clinical investigations for years, and several hypotheses
have been raised, including protein permeability factor sug-
gested by Savin’s group [21], soluble urokinase type plasmin-
ogen activator receptor (suPAR) [24], cardiothropin-like cyto-
kine 1(CLC-1) [13], and anti-CD40 antibody [4]. The hypoth-
esis of circulating factor(s)-related mechanism of post-
transplant recurrence of nephrotic syndrome is translated into
therapeutic protocols, including plasmapheresis (to remove
the factor(s)) [17, 18], corticosteroids (to stabilize the cyto-
skeleton of podocytes and reduce podocytes apoptosis) [19],
cyclosporine A (to stabilize the cytoskeleton of podocytes)
[5], and rituximab (monoclonal antibody depleting B CD20
cells) to deplete the cytokines-producers [7, 15]. There are
conflicting data on efficacy of rituximab used for treatment
of post-transplant recurrence of nephrotic syndrome in adult
and pediatric patients. The purpose of our study was to present
the summary of our experience with the efficacy and safety of
rituximab in five children after first renal transplantation, who
presented rapid recurrence of nephrotic syndrome.
Patients and methods
A retrospective chart review was performed and included five
children at the age from 5 to 12 years (at the day of renal
transplantation), who presented immediate (day 1 or 2) recur-
rence of nephrotic syndrome (NS) post-transplant. The crite-
rion of chart selection was the use of rituximab for the treat-
ment of NS recurrence after transplantation. The drug-
resistant nephrotic syndrome was the underlying cause of
end-stage renal disease. Focal segmental glomerulosclerosis
(FSGS) was present in native renal biopsy in two patients,
mesangial-proliferative glomerulonephritis (MesPGN) in
two, and minimal change nephrotic syndrome (MCNS) in
one case. One patient had confirmed heterozygous podocine
(NPHS2) genetic mutation (p.R229Q). There was 3 to 8 years
interval between introducing dialysis and primary renal trans-
plantation. There were four deceased donor-related and one
living-related transplantation performed, the last one in a pa-
tient with genetic podocine mutation (patient’s father was a
donor). All patients received triple immunosuppression
(CsA+MMF+Pred). All five demonstrated immediate recur-
rence of nephrotic syndrome (four on the day 1 and one on the
second day post-transplant), with gross proteinuria and
oliguria. Plasmapheresis was introduced in all five patients,
and in four cases, rituximab was directly added to the protocol
at the dose of 375 mg/m2 on weekly basis. In one case, the
introduction of rituximab was delayed due to primary prom-
ising effect of plasmapheresis; however, once the patient be-
came plasmapheresis-dependent, the drug was added during
fourth month post-transplant [8]. Four patients received four
weekly doses, and in one case the drug administration was
limited to two doses due to severe relapsing infections The
count of B CD19 cells was monitored on weekly and then
monthly basis by flow cytometry. The clinical characteristics
and treatment course in summarized in Table 1. The complete
remission was achieved in two patients (no. 1 and no. 3), with
complete depletion of B CD19 for up to 4 and 2 months (after
last dose of rituximab), respectively, and with no adverse
drug-related adverse events. The remission was sustained
within 7 and 5 years of follow-up, respectively, with no spe-
cific treatment beyond standard triple immunosuppression
(CsA+MMF+Pred). Only partial remission (significant,
however floating proteinuria; from 0.4 to 3.5 g and from 0.5
to 2.0 g/24 hours; respectively) was seen in two cases (no. 4
and no. 5), presenting complete B CD19 depletion up to 7 and
4 months after treatment, respectively. Serious adverse events
were present in these two cases, including relapsing severe
infections (blood culture was positive for Klebsiella
pneumoniae) (case no. 4), which limited the number of sched-
uled rituximab doses to 2 and severe acute lung injury (RALI)
(case no. 5). Patient no. 4 lost the graft 2.5 years after trans-
plantation due to chronic nephropathy. Patient no. 5 died due
to non-infectious rapid lung fibrosis. There was no therapeutic
effect at all in the case no. 2, who was also finally given oral
galactose; however, the graft was never functioning and was
removed 7 months post-transplant.
Discussion
Rituximab has been used for treatment of post-transplant ne-
phrotic syndrome for a decade, and initial reports were in
favor to the drug efficacy [7, 12, 16]. Our preliminary experi-
ence (case no. 1) was also very positive [8] and encouraged us
to use this protocol. The reports published later on have
revealed the conflicting data on clinical efficacy. Published
13 studies (mainly case reports or case series reports) included
overall 44 pediatric patients treated with rituximab for post-
transplant recurrence of nephrotic and among those 27 pa-
tients (55 %) presented complete remission, 14 (28.5 %)
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partial remission of nephrotic syndrome, and no effect was
present in the remaining 8 (16.5 %) cases [14].
Rituximab was always used in combination
with plasmapheresis and other drugs
It must be noted that most of the reported patients, treated for
recurrence of nephrotic syndrome after renal transplantation
with rituximab, underwent the combined therapy with plasma
exchange and post-transplant triple immunosuppression in-
cluding calcineurine inhibitors, steroids, and antiproliferative
drugs, so the final clinical effect (if positive) might be the
summary result of several therapeutic mechanisms.
Moreover, the timing of introduction and the number of ritux-
imab doses used in this setting was variable, as the drug was
given also preemptively (as prophylaxis) at the day of trans-
plantation [6] or as rescue therapy of overt recurrence of ne-
phrotic syndrome [7, 12, 16, 22]. The number of doses
ranged from single to six weekly doses of 375 mg/m2. The
correlation between B CD20/CD19 cells depletion and clinical
effect was also variable [14]. Among patients described in our
report, four (out of five) have received rituximab as first-line
therapy, and in remaining one, the drug was prescribed as
second-line treatment due to persistent dependency from plas-
mapheresis. In four of our cases, four fixed weekly doses of
375 mg/m2 were given, and in remaining one, the number of
scheduled doses was limited to two, due to relapsing infec-
tions. It is not clear whether the time interval (shorter versus
longer) between post-transplant NS recurrence and introduc-
tion of rituximab is important for the overall efficacy of this
intervention. Some authors expressed such suggestion in the
discussion of their reports; however, there is no evidence so
far. Almost universally, rituximab therapy was combined with
plasmapheresis, and other suggestions stated that rituximab
should be introduced early after the evidence of plasmaphere-
sis failure [10, 12, 22].
Why the efficacy of rituximab is variable
It is not clear, whether the lack of significant clinical effect in
three (of five) of our cases is related to specificity of this
particular setting of the patients, in whom the recurrence was
immediate (day 1 or 2), which may suggest the high
concentration/activity of hypothetic circulating factors.
Unfortunately, at the time of this treatment the evaluation of
suPAR concentration in serum or urine was not available. The
clinical course of these cases also show that long waiting time
on dialysis (from 3 to 8 years) has no protective effect in terms
of risk of rapid recurrence of nephrotic syndrome, as was
carefully suggested based on some clinical observations [2].
Using similar approach, we faced two successful and three
disappointing cases. B cells depletion was achieved in all
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rituximab was effective in terms of pharmacodynamics activ-
ity, independent from the absence of clinical effect in those
patients, who did not respond. This might correspond with the
data on B cell-independent mechanism of rituximab, which
may act via regulation (preservation) of sphingomyelin phos-
phodiesterase acid-like 3b (SMLPD-3b), a protein which is
involved in the podocyte cytoskeleton activity [6]. The anec-
dotal use of galactose in case no. 2, based on hypothesis of
local inhibition of protein permeability factor in podocytes by
galactose, was not effective either [20, 21]. Probably achiev-
ing (or not) the complete remission in particular cases is the
effect of random targeting (or not) the patient, in whom the
mechanism of nephrotic syndrome is directly related to abnor-
mal activity of B cells. It is also possible that partial efficacy is
related to B-independent manner of rituximab action [6].
Interestingly, the complete depletion of B cells was also pres-
ent in our case no. 2, who showed complete resistance to
rituximab, suggesting that there are specific cases, in whom
neither B cell-dependent nor B cell-independent (local) mech-
anisms of the drug are relevant to reduce heavy post-transplant
proteinuria. This is possible that this patient had T cell-
dependent mechanism of the disease; however, plasmaphere-
sis, which theoretically should be helpful in removing T cell
driven cytokines (such as IL-13 stimulating local expression
of CD80 molecule in podocytes) [3], was not effective either.
Current experience on potential of use of abatacept (specific
inhibitor of CD80) in post-transplant recurrence of NS, resis-
tant to plasmapheresis, and rituximab [25] was not known at
the time when our case was treated.
Unfortunately, we are still at an early stage of
distinguishing the different patterns of the mechanisms of
post-transplant nephrotic syndrome; however, recent data on
the use of diagnostic tool to identify patients at high risk of
FSGS recurrence are encouraging [4].
One of our patients had heterozygous mutation of podocine
and received living-related transplant. There were some re-
ports on recurrence of nephrotic syndrome after renal trans-
plantation in children with podocine genetic mutations, with
high variety in terms of post-transplant time to proteinuria
(range 4 to 10 years). The final outcome of reported six cases
was good [11]. As the recurrence was immediate (first day) in
our case, we presume that she presented combined, genetic
defect and immunological injury, and the latter one was the
major cause of rapid recurrence.
Safety concern
Another issue is safety of this protocol. We have faced
two cases of severe adverse events, including severe
recurrent bacterial infections in case no. 4 suggesting
overimmunosuppression. The most significant adverse
event was RALI (rituximab-associated acute lung injury) in
case no. 5, which was reported in details as case report [9].
The risk/benefit ratio is then individual and must be taken into
consideration.
In summary, we present disappointing results of rituximab
plasmapheresis-based rescue protocol of treating immediate
recurrence of post-transplant nephrotic syndrome. It is un-
clear, whether aggressive pattern of immediate recurrence
was the reason of the treatment failure in three cases. Center
experience was the reason of the evolution of our attitude in
terms of using this protocol, from enthusiastic to reluctant.
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